Production line shut down, subsidiary shut down How does the enterprise break through in the environmental protection storm?

[industry trends of pharmaceutical network] recently, Yan'an Bikang pharmaceutical, a listed company, announced that it would shut down its production line with an annual capacity of 2000 tons due to factors such as anti drug restriction and environmental protection At the same time, a subsidiary of the company was shut down To some extent, this is a small epitome of the current domestic API industry In fact, under the background of continuous upgrading fermentation of "anti restriction order" and never relaxation of environmental protection pressure, enterprises are faced with double pressure of high cost and profit of environmental protection technology promotion, so it is not difficult to understand the decision of exit As a traditional chemical enterprise, the production equipment and process are difficult to meet the increasingly strict environmental protection requirements A large amount of human and financial resources need to be invested in the follow-up rectification It is better to directly shut down some single product production lines to reduce the investment and environmental protection policy pressure From 2012 when the state issued the plan for prevention and control of water pollution in key basins to January 2015 when the new environmental protection law was issued, to 2016 when the environmental protection tax law was issued, to 2017 when the Ministry of environmental protection issued the work plan for prevention and control of air pollution in Beijing, Tianjin, Hebei and surrounding areas in 2017 (Draft for comments) In addition, China's environmental protection tax has been formally levied since April 1, 2018 According to the regulations on the management of the list of key pollutant discharge units (for Trial Implementation), API manufacturing and pharmaceutical are respectively included in the list of key pollutant discharge units of water environment and the list of key pollutant discharge units of atmospheric environment These sustained policies are constantly testing the ability of pharmaceutical enterprises to survive and operate The increasingly strict supervision of environmental protection has not only increased the environmental protection expenditure of API enterprises, but also forced more small capacity enterprises to withdraw from the market There are opinions in the industry that 70% of small and medium-sized APIs may fall in the future Under this influence, more and more pharmaceutical enterprises begin to focus on the main business, and the determination to focus on industry and become the main business is gradually revealed The action of Yan'an Bikang Pharmaceutical Co., Ltd is also a microcosm of API industry: constantly optimizing product structure, realizing industrial upgrading, increasing industry concentration and transforming to API development Under the policy of "order of limited resistance", how to break through the "order of limited resistance" is only one of the ways for the country to strictly manage the pharmaceutical industry Some insiders said that under many new medical policies, the development of enterprises must see clearly the environment and grasp the trend "Compliance" will be the basis for the future survival and development of the enterprise It is necessary to shift from barbaric growth to comprehensive compliance, establish correct industrial values of the pharmaceutical industry, and rationally respond to major industrial changes It is worth noting that with the release of the New Guiding Catalogue of industrial restructuring issued by the national development and Reform Commission, it is very clear which enterprises in the pharmaceutical industry are encouraged and which are facing elimination This also provides a certain reference value for the development of pharmaceutical enterprises in the future The pharmaceutical fields encouraged in the catalogue may become the main development direction of enterprises, including the development and application of drugs and new treatment methods It specifically covers the development and production of new drugs with independent intellectual property rights, the development and production of natural drugs, the development and production of new drug dosage forms, new auxiliary drugs, children's drugs and medicines in short supply, the development and application of new technologies in the drug production process, the optimization of production technologies of basic drugs and APIs, and the development and application of new pharmaceutical preparations For unmet clinical needs, we will promote the use of modern biotechnology to transform traditional production processes and vigorously promote new drug research and development means It includes vaccines for major diseases, antibodies, gene therapy and other new therapeutic drugs And these encouraged areas have the opportunity to become the development opportunities for the transformation and upgrading of enterprises Therefore, in the face of increasingly strict environmental control, we should not only see its pressure on enterprises, but also see its role in promoting At present, some enterprises have begun to become new competitiveness in the industry after a large amount of investment in environmental protection transformation and upgrading For example, projects such as CHUANNING of Kelun Pharmaceutical Co., Ltd have been criticized for their environmental protection problems However, with heavy investment in environmental protection, they are gradually becoming new and powerful competitors in the field of antibiotics Generally speaking, environmental protection has become the trend of sustainable development of pharmaceutical industry in the future Under the background of constantly changing industry pattern and stricter supervision, the pharmaceutical enterprises with advanced environmental protection strategy, green production and high technology and added value can create more stable profits and less affected by policies.